Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment

"We are delighted to expand this strategic alliance with NC State and our Scientific Advisory Board member, Dr. Glenn Cruse," saidRobb Knie, CEO of Hoth Therapeutics.